(Q58860298)

1

0 references

Jinhong Feng

3

0 references

Hao Fang

4

0 references

Wenfang Xu

Medicinal Chemistry Research

5

0 references

publication date

3 December 2010

0 references

published in

0 references

volume

21

0 references

issue

2

0 references

page(s)

152-156

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s00044-010-9519-7

0 references

cites work

Genomewide studies of histone deacetylase function in yeast

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Control of Smad7 stability by competition between acetylation and ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Identifying Novel Type ZBGs and Nonhydroxamate HDAC Inhibitors Through a SVM Based Virtual Screening Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

A fast flexible docking method using an incremental construction algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

The structure and function of histone deacetylases: the target for anti-cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7

Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00044-010-9519-7